92 128

Cited 0 times in

A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane

 Jun Yong Park  ;  Chul Kim  ;  Joo Hyuk Sohn  ;  Yong Tae Kim  ;  Sun Young Rha  ;  Woo Ick Jang  ;  Gwi Eon Kim  ;  Hyun Cheol Chung 
 CANCER RESEARCH AND TREATMENT, Vol.34(4) : 274-279, 2002 
Journal Title
Issue Date
Chemotherapy ; Gemcitabine ; Metastatic breast neoplasm
Purpose: We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine antimetabolite, in patients, who had previously failed anthracycline and taxane-based chemotherapy for the treatment of metastatic breast cancer. Materials and Methods: Twenty-one patients with metastatic breast cancer, which was unresponsive to previous chemotherapy, were entered into this study. Gemcitabine was administered at 850 mg/m2, as a 60- minute intravenous infusion on days 1, 8 and 15. This regimen was repeated every 28 days with G-CSF support, but without dose reduction. Results: Objective responses were seen in 6 of the 20 patients who were able to be evaluated (1 complete response and 5 partial responses), with an objective response rate of 30%. The median time to progression was 5 (1∼20) months, and the median overall survival duration was 11 (2∼21) months. The actual dose intensity was 566.7 mg/m2/wk (range; 340∼637.5 mg/m2/wk) and the relative dose intensity was 0.89 (range; 0.40∼1.00). Toxicity was mainly hematological. Toxicities included: grade 3 neutropenia in 20% and anemia in 5%. Grades 3 and 4 thrombocytopenia occurred in 15% of the patients. Conclusion: Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen.
Files in This Item:
T200205630.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.